EXAS Quote, Financials, Valuation and Earnings

Guardant Health has a net margin of -14.32% compared to Exact Sciences's net margin of -46.77%. Exact Sciences's return on equity of -35.57% beat Guardant Health's return on equity of -8518.58%.

Exact Sciences has a consensus price target of $68.81, signalling upside risk potential of 29.03%. On the other hand Guardant Health has an analysts' consensus of $58.89 which suggests that it could grow by 33.7%. Given that Guardant Health has higher upside potential than Exact Sciences, analysts believe Guardant Health is more attractive than Exact Sciences.

Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Guardant Health has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.904%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $706.8M, which are larger than Guardant Health quarterly revenues of $203.5M. Exact Sciences's net income of -$101.2M is lower than Guardant Health's net income of -$95.2M. Notably, Exact Sciences's price-to-earnings ratio is -- while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.49x versus 7.02x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -14.32% compared to Exact Sciences's net margin of 16.94%. Exact Sciences's return on equity of -35.57% beat Illumina's return on equity of -35.09%.

Exact Sciences has a consensus price target of $68.81, signalling upside risk potential of 29.03%. On the other hand Illumina has an analysts' consensus of $115.55 which suggests that it could grow by 47.81%. Given that Illumina has higher upside potential than Exact Sciences, analysts believe Illumina is more attractive than Exact Sciences.

Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Illumina has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.945%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $706.8M, which are smaller than Illumina quarterly revenues of $1.1B. Exact Sciences's net income of -$101.2M is lower than Illumina's net income of $187M. Notably, Exact Sciences's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.49x versus 2.85x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of -14.32% compared to Exact Sciences's net margin of 6.36%. Exact Sciences's return on equity of -35.57% beat Labcorp Holdings's return on equity of 9.01%.

Exact Sciences has a consensus price target of $68.81, signalling upside risk potential of 29.03%. On the other hand Labcorp Holdings has an analysts' consensus of $271.28 which suggests that it could grow by 9.91%. Given that Exact Sciences has higher upside potential than Labcorp Holdings, analysts believe Exact Sciences is more attractive than Labcorp Holdings.

Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.43%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings offers a yield of 1.17% to investors and pays a quarterly dividend of $0.72 per share. Exact Sciences pays -- of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exact Sciences quarterly revenues are $706.8M, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Exact Sciences's net income of -$101.2M is lower than Labcorp Holdings's net income of $212.8M. Notably, Exact Sciences's price-to-earnings ratio is -- while Labcorp Holdings's PE ratio is 28.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.49x versus 1.58x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of -14.32% compared to Exact Sciences's net margin of -11.3%. Exact Sciences's return on equity of -35.57% beat Natera's return on equity of -21.3%.

Exact Sciences has a consensus price target of $68.81, signalling upside risk potential of 29.03%. On the other hand Natera has an analysts' consensus of $187.72 which suggests that it could grow by 19.28%. Given that Exact Sciences has higher upside potential than Natera, analysts believe Exact Sciences is more attractive than Natera.

Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Natera has a beta of 1.794, suggesting its more volatile than the S&P 500 by 79.445%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $706.8M, which are larger than Natera quarterly revenues of $476.1M. Exact Sciences's net income of -$101.2M is lower than Natera's net income of -$53.8M. Notably, Exact Sciences's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.49x versus 11.57x for Natera. Usually stocks with elevated PS ratios are considered overvalued.